StimLabs(R) announces commercial launch of DermaForm(TM), a uniquely engineered collagen scaffold particulate device. November 3, 2026 ROSWELL, Ga., Nov. 3, 2026 /PRNewswire/ - StimLabs(R), a leading regenerative medicine company, today announces the commercial launch of DermaForm(TM), an FDA 510(k)-cleared porcine-derived particulate collagen scaffold that manages a range of acute and chronic wounds. DermaForm was developed by Geistlich and is distributed exclusively in the U.S. by StimLabs, the latest product to come out of the companies' continued partnership. An intentionally designed, porous collagen-based scaffold engineered to support wound management and tissue protection, DermaForm's pore sizes are within the range of pore sizes that are known to be accessible for cell infiltration. DermaForm is biocompatible with low immunogenicity which supports use in the management of wounds and naturally resorbs into the wound bed over time. DermaForm is a uniquely engineered particulate device that provides a scaffold for your patients' wound needs - a structure to support the wound as it heals. The particulate format of DermaForm allows for versatile application, in method, density of coverage, and hydration level. DermaForm is ready to use with direct application from the vial. The particulate is able to fill wound voids and cover large wound surface areas and may be applied dry and directly into the wound bed or in a rehydrated state. It is easily moldable to a desired consistency based upon the amount of fluid added. DermaForm protects the wound when primary closure is not possible and the format is beneficial for large, complex hospital wounds. "DermaForm represents exactly the kind of differentiated, first-in-class solution that defines StimLabs' approach to building our portfolio," said John Daniel, Founder and CEO of StimLabs. "There is a significant unmet need in the management of large, complex, and hard-to-heal wounds, and DermaForm was purpose-built to address it. Its unique porcine source, collagen scaffold architecture, and versatile particulate format give clinicians a new solution for their wound care needs. We are proud to bring this innovation to patients across the country." Tom Dion, EVP & Chief Commercial Officer at StimLabs, added, "DermaForm fills a clear gap in the wound care toolkit. Clinicians managing large, complex wounds need a product that is not only effective but also practical - easy to apply, easy to store, and easy to incorporate into their existing workflow. DermaForm delivers on all three. It is shelf-stable at room temperature, pourable directly from the vial, and has the inherent benefits of a particulate device. We expect strong uptake from hospital-based wound care teams." David Wemans, VP Regenerative Technologies at Geistlich, commented, "DermaForm is the result of Geistlich's deep scientific expertise in collagen engineering applied specifically to the unmet needs of complex wound management. The product is a combination of deliberate design choices aimed at providing clinicians with a unique product that solves a clinical unmet need. We are confident that clinicians will see meaningful outcomes with this device, and we are proud to bring it to U.S. patients through our partnership with StimLabs." About StimLabs StimLabs is a pioneer in advancing the state of regenerative medicine, with a current focus in wound care and surgical applications. Comprised of industry leaders, StimLabs is dedicated to offering patients the best possible care while recognizing the urgency of providing solutions in areas with unmet needs. StimLabs has a comprehensive product portfolio addressing various clinical applications and has established a strong intellectual property catalog. Committed to delivering superior products, StimLabs is a trusted partner to physicians and patients alike. About Geistlich Geistlich is a global leader dedicated to advancing regenerative medicine. The company has been the world market leader in the field of regenerative dentistry for many years. In addition, Geistlich is committed to providing comprehensive support to clinicians in the field of regenerative medicine through scientific research, innovative developments as well as educational programs. Geistlich is a Swiss family-owned company with tradition since 1851. With 15 subsidiaries and 120 distributors, the company reaches over 100 markets and employs around 900 people. SOURCE StimLabs Published November 03, 2026 January 5, 2015 January 7, 2015 January 13, 2015

Germfree unveils next chapter of growth with expanded executive leadership and refreshed brand. - Adam Simon joins as CFO and Geoffrey Schwartz as CCO as Germfree strengthens the leadership and capabilities required for its next phase. ORMOND BEACH, Fla., September 23, 2026 - Germfree, a full-lifecycle engineering and manufacturing partner for mission-critical environments across life sciences, healthcare and biocontainment, today announced the appointment of Adam Simon as Chief Financial Officer and Geoffrey Schwartz as Chief Commercial Officer, alongside a refreshed brand identity and redesigned Germfree.com. Together, Simon and Schwartz add two capabilities central to Germfree's growth: the financial and operating architecture required to scale a more sophisticated enterprise, and the commercial leadership required to stay closely connected to customers and markets. The moves reflect a broader evolution underway at Germfree as the company builds for its next era of growth. Simon will focus on building the financial and operating infrastructure required for the company's next stage - moving Germfree toward greater enterprise-level discipline and creating a scalable platform capable of supporting both organic growth and, over time, a broader portfolio of complementary businesses. Schwartz will help deepen Germfree's customer and market strategy as the company expands its role as a strategic partner across life sciences and healthcare. Across advanced therapies, biomanufacturing, hospital and compounding pharmacy, and high-containment applications, customers are navigating increasingly complex requirements and seeking partners capable of taking greater accountability across critical infrastructure, equipment and lifecycle support. Germfree's refreshed tagline, Made for Mission Critical, puts language around the role the company has played since 1962 designing, building and supporting environments where safety, reliability and execution matter. "Germfree has spent more than six decades earning the right to work on programs where execution truly matters," said Carol Houts, CEO of Germfree. "What we are doing now is building the company that can carry that legacy forward at a much greater scale. Made for Mission Critical is more than a tagline. It defines the standard we expect of ourselves and the promise we make to our customers." As part of that evolution, Germfree has strengthened its executive leadership team with two leaders whose experience directly supports the company's next phase. Simon joins Germfree as Chief Financial Officer after serving as Senior Vice President of Finance at regenerative medicine company StimLabs, following 15 years serving private equity portfolio and family owned businesses at PwC. He brings a combination of financial rigor, operating experience and life sciences industry knowledge. "Germfree has significant opportunity ahead and realizing that opportunity requires us to build for the company we intend to become, not simply the company we are today," said Simon. "My focus is on creating the financial discipline, operating infrastructure and visibility needed to scale the enterprise responsibly and support its continued evolution." Schwartz joins Germfree as Chief Commercial Officer with nearly three decades of life sciences leadership experience. Most recently, he served as CEO and General Manager of Mirus Bio and previously as the company's Chief Commercial Officer, including through its acquisition by MilliporeSigma. "Our customers are solving increasingly complex problems and need partners who understand how facilities, equipment, process and lifecycle support come together," said Schwartz. "Germfree has the opportunity to bring those capabilities together in a highly differentiated way, and I am excited to help build that future." Geoffrey Schwartz, CCO. Adam Simon, CFO. "Adam and Geoff are important additions because they bring capabilities that are essential to where Germfree is going," Houts said. "Adam is helping us build the financial and operating architecture of a larger, more sophisticated enterprise, while Geoff brings deep life sciences market knowledge and a customer perspective shaped by decades in the industry. Both understand that sustainable growth begins with execution." Germfree's continued evolution also includes the integration of Arcoplast, acquired in 2025, as well as ongoing investment across its cleanroom, containment, pharmacy, equipment and lifecycle service platforms. The refreshed identity and redesigned Germfree.com bring those capabilities together under a more unified expression of the company and its purpose. "This is not about changing who Germfree is," Houts said. "It is about being much clearer about what has always made this company special - and building the organization required to deliver on that promise at a greater scale." The refreshed Germfree identity is live now at Germfree.com. About Germfree Germfree is a full-lifecycle engineering and manufacturing partner for mission-critical environments across life sciences, healthcare and biocontainment. For more than six decades, Germfree has designed, engineered, manufactured, integrated, installed and supported mobile and modular cleanrooms, containment systems, pharmacy solutions and critical equipment for organizations operating where safety, compliance and reliability are essential. Germfree. Made for Mission Critical. Media Contacts: Germfree Laboratories Dex Williams, Director of Go-To-Market Operations [email protected] Share page: